Human Fertilisation and Embryology Authority (HFEA)

The Human Fertilisation and Embryology Authority (HFEA) is the UK’s statutory regulator for fertility treatment and embryo research, created by the Human Fertilisation and Embryology Act 1990 and operational since August 1991. It is the licensing and inspecting body that decides which clinics and research establishments may lawfully create, store, or use human embryos and gametes, and it does this through three distinct licence categories — treatment, storage, and research — each renewed periodically and backed by routine inspection. For research administrators, the HFEA is the licensing counterpart to bodies like the Health Research Authority (HRA): a project involving human embryos typically needs an HFEA research licence in addition to, not instead of, the Research Ethics Committee opinion the HRA/REC system requires for the human participants involved.

What the HFEA licenses

The HFEA’s remit covers activity the Act makes licensable: IVF and other fertility treatment, gamete and embryo storage, and embryo research (including, since the 2008 Act, research using human admixed embryos). It does not regulate every aspect of assisted reproduction — surrogacy arrangements themselves, for example, sit under separate legislation — and its licensing function is distinct from, and does not substitute for, a Research Ethics Committee’s assessment of a study’s ethical merits. A licensed research establishment still needs REC approval for the human participants donating gametes or embryos; the HFEA licenses the establishment’s activity with the resulting embryos, not the ethics of recruiting the donors.

The research licence process

A research licence application goes to the HFEA’s Licence Committee, which assesses it against the Act’s Schedule 2 closed list of permitted research purposes and the establishment’s proposed governance, premises, and personnel. Granted licences typically run for up to three years and are subject to renewal and periodic inspection; the HFEA can attach conditions, and can vary, suspend, or revoke a licence if a centre falls out of compliance. Because Schedule 2 restricts what a research licence can authorise at all, the practical first step for any UK embryo-research proposal is usually confirming which of the seven Schedule 2 purposes it fits, before the licensing conversation with the HFEA begins in earnest.

The Code of Practice

The HFEA’s Code of Practice is the operational document licensed centres actually work from day to day — distinct from the Act’s bare statutory text, it translates the law into specific, numbered guidance notes covering consent documentation, storage limits, donor information, quality and governance systems, and incident reporting, among other topics. It is currently in its 9th edition (version 9.4, effective 26 October 2023), which updated 17 of the Code’s 33 guidance notes to reflect 2022 changes to gamete and embryo storage-limit law, CE-marking requirements for medical devices used in treatment, egg-sharing arrangements, complaints handling, and “rescue” ICSI procedures. The Code sits alongside the HFEA’s General Directions (binding requirements issued under the Authority’s own statutory powers) as the two main instruments through which the HFEA translates the Act into day-to-day licence conditions; both are revised periodically as practice, technology, and the law itself change, so a licensed centre’s compliance obligations are not fixed at the point of the Act’s original text.

Governance structure

The HFEA operates through statutory committees rather than as a single undifferentiated regulator: the Licence Committee decides individual licensing applications and compliance action, while the Authority itself (the HFEA’s board) sets policy, the Code of Practice, and General Directions. This separation — a body that sets the rules and a distinct committee that applies them to individual applications — is a structural feature research administrators should not assume is unique to research licensing; it applies equally to the HFEA’s treatment and storage licensing functions.

How this differs from the Human Tissue Authority

Research administrators working across both UK regimes should not conflate the HFEA with the separate Human Tissue Authority (HTA), which licenses human tissue and cell activity under the Human Tissue Act 2004. The two statutes and regulators are deliberately non-overlapping: the HFEA and its parent Act cover embryos and, for treatment/research purposes, gametes; the HTA and its parent Act cover human tissue and cells generally, expressly excluding gametes and embryos outside the body from its own scope. A research programme spanning both tissue banking and embryo research can need licences from both regulators for genuinely distinct activities, not one licence covering both.

Practical implications for research administrators

• Confirm which licence category (treatment, storage, or research) a proposed activity actually needs before assuming a single HFEA licence covers everything a project touches — the three categories are not interchangeable.
• Check the current Code of Practice edition and General Directions before relying on a remembered summary of HFEA requirements — both are revised periodically, most recently reflecting 2022 storage-law changes, and superseded guidance can misstate a live compliance obligation.
• Track HFEA licensing status and REC/ethics approval as two separate, concurrently-required items for the same embryo-research project, the same two-track pattern documented for Human Tissue Act research.
• Don’t conflate the HFEA with the Human Tissue Authority — confirm which statute (and which regulator) actually governs the specific material a project uses before applying for the wrong licence.

Frequently asked questions

What does the HFEA regulate?

Fertility treatment, gamete and embryo storage, and embryo research (including human admixed embryo research since 2008) in the UK, through a licensing and inspection regime established by the Human Fertilisation and Embryology Act. It does not regulate human tissue and cells generally — that is the separate Human Tissue Authority’s remit.

Is an HFEA research licence the same as ethical approval?

No. The HFEA licenses the establishment’s activity with embryos against the Act’s Schedule 2 purposes and its own licence conditions; a Research Ethics Committee separately assesses the ethical merits of the study and the consent arrangements for the human participants donating gametes or embryos. Both are usually required for the same project.

What is the HFEA Code of Practice?

The HFEA’s operational guidance document, currently in its 9th edition (version 9.4, effective October 2023), that translates the Human Fertilisation and Embryology Act’s requirements into specific numbered guidance notes covering consent, storage, governance, and incident reporting for licensed centres.

How long does an HFEA research licence last?

Research licences are typically granted for up to three years by the HFEA’s Licence Committee, subject to renewal, periodic inspection, and conditions the Committee can attach, vary, or (in cases of non-compliance) use as grounds to suspend or revoke the licence.

Is the HFEA the same as the Human Tissue Authority?

No, they are separate regulators under separate statutes. The HFEA licenses embryos and, for treatment/research, gametes, under the Human Fertilisation and Embryology Act. The Human Tissue Authority licenses human tissue and cells generally under the Human Tissue Act 2004, which expressly excludes gametes and embryos outside the body from its scope.